Inhaled Corticosteroids In Treatment of Cystic Fibrosis

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 15, 3 Issues, 2016


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Inhaled Corticosteroids In Treatment of Cystic Fibrosis



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 11(3): 206-209.

Author(s): Ela Erdem and Refika Ersu.

Affiliation: Baglarbasi Cad. Toprak Sitesi C/Blok No, 90, Uskudar-Istanbul, Turkiye.

Abstract

Reduction of lung inflammation is one of the goals in the treatment of cystic fibrosis (CF). As a result, antiinflammatory therapies are often used to decrease the excessive and persistent inflammatory response. Although effective, the use of systemic corticosteroids has been limited due to unacceptable adverse effects. Inhaled corticosteroids (ICS) are often used empirically to treat children and adults with CF despite the lack of evidence of their benefit. Concern about effects on growth and adrenal suppression have been reduced, but not eliminated with the use of ICS. Herein, mechanisms of action of corticosteroids, the effectiveness and safety of ICS usage in CF are reviewed.

Keywords:

Inhaled corticosteroids, cystic fibrosis, adverse effects.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 11
Issue Number: 3
First Page: 206
Last Page: 209
Page Count: 4
DOI: 10.2174/1871523011202030206
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science